% | $
Quotes you view appear here for quick access.

Vertex Pharmaceuticals Incorporated Message Board

you are viewing a single comment's thread.

view the rest of the posts
  • thirdmeinvestor thirdmeinvestor Jul 7, 2011 3:07 PM Flag

    vrtx st at ubs at neutral

    Slowly but surely, market analysts are beginning to learn that there is more than Incivek in the Vertex pipeline.

    [> UBS initiated VRTX with a Neutral and price target of $56 saying the co is
    poised to lead a new era of hepatitis-C virus (HCV) antivirals with the recent
    FDA approval of Incivek, which they and the Street view as a potential
    blockbuster opportunity. Further, the HCV program is complemented by a novel
    and potentially transformative cystic fibrosis program, which they believe may
    address the vast majority of CF patients. The firm is initiating coverage of
    Vertex with a Neutral rating despite a near-term and long-term positive
    stance, given valuation.<]

125.60+2.32(+1.88%)May 1 4:00 PMEDT